SightCall Partners with Lavazza Group, Uses AR Visual Assistance for Rapid Remote Maintenance
8.9.2021 11:00:00 EEST | Business Wire | Press release
SightCall, the world’s leading augmented reality (AR)-powered visual assistance platform, today announced its partnership with Italy’s Lavazza Group to offer AR-powered remote visual assistance for customer care and maintenance of its coffee machines. One of the world’s most important coffee roasters and a global enterprise with products and distributors in more than 140 countries, Lavazza Group is accelerating its use of virtual assistance technologies to support the ongoing expansion of its product portfolio and continued efforts to become more responsive to fast-changing consumer needs.
“We are proud to partner with Lavazza Group to provide global service solutions for easier and faster product maintenance and repair,” said Thomas Cottereau, founder and CEO of SightCall. “Now more than ever, the world’s top brands are turning to digital support that allows them to provide issue resolution with minimal service disruption. SightCall will enable Lavazza to work through customer care issues immediately, maintaining their hard-earned reputation for high-quality coffee products.”
SightCall provides the company with a comprehensive visual support tool for customer service agents to guide customers to troubleshoot issues, such as descaling coffee machines or basic accessory maintenance remotely. The AR interface lets remote agents draw, point and highlight onto the customer’s smartphone, and high-definition picture assures the highest call qualities even in low-bandwidth environments. Device-agnostic, SightCall performs on a range of user products from smartphones and tables to specialist equipment such as smart glasses.
Lavazza Group, with more than 4,000 employees and revenues of more than EUR 2 billion (2020 Financial Statement), switched to SightCall from a previous visual assistance provider. This decision stemmed from its desire to move from a local approach to a global template offering maximum portability and seamless CRM integration, reinforced by strong GDPR compliance.
Lavazza first piloted SightCall with its customer service teams in France and Germany in the middle of the COVID-19 lockdown in April. Customer support teams were impressed by the ease of use and the level of confidence quickly developed with the tool, providing them with good insight into how a long-term partnership would work.
The company has plans to scale up usage to 130+ customer support agents in seven countries over the next three years. The company plans to cover multiple regions of the world where it provides products, bolstered by the SightCall app’s ability to operate in 13 different languages. Lavazza will also increase the number of codes and use cases it applies SightCall to, with more readily available data from its CRM and responses to SightCall customer surveys telling it where visual assistance can best be deployed to resolve maintenance issues.
“Everywhere our coffee is consumed, Lavazza innovates to enhance the experiences of our customers and consumers, providing fast and accessible service when and where they need it,” said Maria Cristina Aspesi, Lavazza Group Customer Care Director. “With SightCall, we have chosen a solution that gives both central and local customer care teams a single, cutting-edge tool to help customers and consumers, increasing the number of support and interaction cases that can be solved instantaneously.”
About SightCall
SightCall is the world’s leading augmented-reality powered video cloud platform, delivering live, remote interactions between business and customers on every continent around the globe. In a connected, mobile-first world, businesses leveraging SightCall have the ability to see what their customers see and guide them remotely. With nearly 15 years of experience in remote video assistance, SightCall helps businesses transform their customer service and field service with the power of augmented reality and live video. The company has offices in San Francisco (HQ), Austin, Boston, Frankfurt, London, Melbourne, Paris and Singapore. Visit sightcall.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005412/en/
Contact information
Katie Smart
katie.smart@sightcall.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom